Competitive Landscape and Advantages, page-3

Yes, it would definitely be beneficial for the analysis, although I’m not your analyst, nor are you paying me.

The intended purposes are fairly obvious, in my opinion. The goal is to make diagnosing cardiological problems easier, which ultimately leads to more business for cardiologists, hospitals and their suppliers. The other overarching benefit is to save lives.

In my opinion, EchoIQ doesn’t seem to have any significant legal or regulatory advantages compared to other firms that have already received FDA approval. If there are any legal advantages at this stage, it’s simply that any company with FDA approval is ahead of the game. However, I don’t think this battle will be won on regulatory approval or large clinical dataset of echocardiograms alone, as these can be easily replicated and there is there’s room for multiple players. This battle will be won on continuous innovation and reinvestment in R&D and product design, strong partnerships and collaborations, scalability and adaptability and the financial advantages listed above.